- Report
- May 2025
- 191 Pages
Global
From €3126EUR$3,545USD£2,697GBP
€3474EUR$3,939USD£2,996GBP
- Report
- May 2025
- 186 Pages
Global
From €3126EUR$3,545USD£2,697GBP
€3474EUR$3,939USD£2,996GBP
- Report
- May 2025
- 181 Pages
Global
From €3126EUR$3,545USD£2,697GBP
€3474EUR$3,939USD£2,996GBP
- Report
- May 2025
- 186 Pages
Global
From €3126EUR$3,545USD£2,697GBP
€3474EUR$3,939USD£2,996GBP
- Report
- May 2025
- 197 Pages
Global
From €3126EUR$3,545USD£2,697GBP
€3474EUR$3,939USD£2,996GBP
- Report
- April 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,416GBP
- Report
- April 2025
- 250 Pages
Global
From €3960EUR$4,490USD£3,416GBP
- Report
- April 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,416GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1764EUR$2,000USD£1,521GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1323EUR$1,500USD£1,141GBP
- Report
- July 2024
- 200 Pages
Global
From €4365EUR$4,949USD£3,765GBP
- Report
- September 2022
- 232 Pages
Global
From €3087EUR$3,500USD£2,662GBP
- Report
- October 2022
- 270 Pages
Global
From €3307EUR$3,750USD£2,853GBP
- Report
- May 2022
- 196 Pages
Global
From €2315EUR$2,625USD£1,997GBP
€4630EUR$5,250USD£3,994GBP
- Report
- May 2024
- 139 Pages
Global
From €5732EUR$6,499USD£4,944GBP
- Report
- September 2021
- 111 Pages
Global
From €3969EUR$4,500USD£3,423GBP
- Report
- August 2022
- 118 Pages
Global
From €3969EUR$4,500USD£3,423GBP
- Report
- May 2024
- 200 Pages
Global
From €3660EUR$4,150USD£3,157GBP
- Report
- April 2023
- 160 Pages
Global
From €4365EUR$4,949USD£3,765GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2425EUR$2,750USD£2,092GBP

Certolizumab is a monoclonal antibody used to treat immune disorders. It is used to treat a variety of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. It works by blocking the action of a protein called tumor necrosis factor (TNF), which is involved in the body's inflammatory response. Certolizumab is administered as an injection, usually once every two weeks.
Certolizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is one of several drugs used to treat immune disorders, and is often used in combination with other medications. It is generally well-tolerated, with few side effects.
Some companies in the Certolizumab market include UCB, Pfizer, and AbbVie. Show Less Read more